ANZAN 2024 Novartis Posters 


Patient and Physician Perspectives on the Wearing-Off Effect in Multiple Sclerosis: Results from Structured Interviews

Presenter: John Parratt

Click to View



Prognostic Value of On-Treatment Serum Neurofilament Light Chain for New or Enlarging T2 Lesions in People With Relapsing Multiple Sclerosis: Pooled Analysis of the ASCLEPIOS I/II Trials

Presenter: Jeanette Lechner-Scott

Click to View



Longer-term Safety and Efficacy of Ofatumumab in People With Relapsing Multiple Sclerosis for Up to 6 years

Presenter: Suzanne Hodgkinson

Click to View



Cumulative Pregnancy Outcomes in Patients With Multiple Sclerosis Following Maternal Exposure to Ofatumumab: Results From the Novartis Safety Database

Presenter: Naomi Burke

Click to View



Characterizing the use of ofatumumab - a Secondary Use of Data Study characterizing ofatumumab utilisation in relapsing multiple sclerosis patients (EAFToS)

Presenter: Anneke Van Der Walt

Click to View



Utilisation of High Efficacy Therapy for Managing Multiple Sclerosis in Australia

Presenter: Pamela McCombe

Click to View



Real-world Australian experience with Ofatumumab in the MSBase Registry

Presenter: Margaret Migocki

Click to View


The content of this page is provided for the purpose of medical education only, and may include information on unregistered products or off-label topics. Please review the Australian Product Information before prescribing, available at The views expressed are those of the speakers and do not necessarily reflect those of Novartis.

Medical Information Service

Medical Enquires, Information services, Adverse Events and Product Complaints please contact:

phone icon

Telephone: 1800 671 203

Colleagues are available from 9:00 to 17:00 from Monday to Friday

Please review Product Information before prescribing available at
For medical enquiries please contact 1800 671 203.

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at

For Ofatumumab prescribing information, please click here.
For Ofatumumab PBS status, please click here.

For Siponimod prescribing information, please click here.
For Siponimod PBS status, please click here.

Novartis Pharmaceuticals Australia Pty Limited. ABN 18 004 244 160. 54 Waterloo Road, Macquarie Park, NSW 2113. ©2023 Novartis Pharmaceuticals Australia Pty Limited.
AU-26174. Date of preparation: May 2024.